002907.SZ Stock Analysis
00
Avoid
Based on Eyestock quantitative analysis, 002907.SZ`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical and Chinese medicine. The company is headquartered in Chongqing, Chongqing and currently employs 1,467 full-time employees. The company went IPO on 2017-10-20. The firm operates three segments: Pharmaceutical Industry segment, Commercial Circulation segment and Retail segment. The firm's products are categorized into the pharmaceuticals of digestive system, nervous system, otorhinolaryngology, cardiovascular and cerebrovascular systems and immune systems. The Company’s products include Weidimei (aluminum carbonate tablets), Ganju Bingmei Tablets, Bawei Qilong Particles, Liuwei Anshen Capsules, Sodium Ferulate for Injection, Omeprazole Sodium for Injection and Gabexate Mesilate for Injection. The firm mainly distributes its products in domestic market.